Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

IJMDC. 2020; 4(1): 240-243


The effect of Sitagliptin on carotid artery atherosclerosis in type2 diabetes mellitus: a systematic review

Maryam Hussain Al-Ayesh, Abdullah Jafar Albariqi, Fatimah Salman Alramadhan, Abdullah Ibrahim Mohammed Alfawzan, Manal Mustafa Alghazal, Majed Abdulaziz Almajdui.




Abstract

Besides the diet and lifestyle modifications usually administered during T2D therapy, oral hypoglycemic drugs is also found to play an important role. Metformin is usually preferred as an initial pharmacological agent for T2D and if metformin monotherapy fails to achieve or maintain the hemoglobin A1c within a period of 3-6 months, usually a second drug is added to control glycemia. Among the add-on therapy options available, Sitagliptin, dipeptidyl peptidase-4 inhibitors are one of the recent and widely used drugs. The current review was aimed at exploring the effect of Sitagliptin on carotid artery atherosclerosis in type 2 diabetic patients. Multiple databases were employed in the literature review, which focused on studies that either reported the association or non-association of a Sitagliptin with carotid artery atherosclerosis. Using appropriate search terms, 8 articles published between analyzed and selected 18 articles published between the years of 2012-2018. The current systematic review concludes that Sitagliptin could be considered as a promising therapy for atherosclerosis in type 2 diabetes mellitus patients.

Key words: Sitagliptin, T2DM, atherosclerosis, carotid artery thickness






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.